Adage Capital Partners
MACK

Adage Capital Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Adage Capital Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-37,958
Closed -$1.5M – 775
2014
Q1 		$1.5M Buy
+37,958
New +$1.62M ﹤0.01% 649

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Adage Capital Partners's MACK Position: Q2 2014 in Review

Adage Capital Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 37,958 shares — an estimated $1.5M sold.

Adage Capital Partners first reported a position in MACK in Q1 2014 and held it in 1 quarter. The position peaked at $1.5M in Q1 2014. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • Adage Capital Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Adage Capital Partners sold 37,958 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $1.5M.
  • Adage Capital Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Adage Capital Partners's Merrimack Pharmaceuticals, Inc. position peaked at $1.5M in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on Adage Capital Partners's 13F filing for Q2 2014, filed 14 Aug 2014.